Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. (2nd July 2016)

• Record Type: Journal Article
• Authors: Allen, Patrick B; Peyrin-Biroulet, Laurent
• Is Part Of: Expert review of clinical immunology. Volume 12:Number 7(2016)
• Page Start: 741
• Page End: 749
• Publication Date: 2016-07-02
• Subjects: Crohn's disease -- Thiopurines -- Methotrexate -- anti-TNF -- Infliximab -- Adalimumab -- Tacrolimus -- Mongersen -- Tofacitinib; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1586/1744666X.2016.1154789
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Crohn's disease (CD) requires treatment beyond symptoms by enabling and maintaining mucosal healing and therefore clinical remission. However, with the increasing use of biologics there have been safety concerns and there is a significant cost implication with the early use of biologics. Therefore, it is imperative that patients with severe/complicated disease or poor prognostic factors are treated with an aggressive strategy while all remaining patients should be treated in a step-up strategy. The potential for disease modification with thiopurines and methotrexate is debated in CD when they are used as a monotherapy. In this review we discuss existing and newer therapies that have recently been developed for CD. We will also provide an algorithm for current management of adult CD patients in routine clinical practice.